X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211246
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211186
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211199
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216481
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211247
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211238
https://www.pharmiweb.com/press-release/2021-02-18/bial-takes-the-lead-in-europe-for-the-commercialisation-of-epilepsy-treatment-zebinix-eslicarbazepine-acetate-expanding-neurology-footprint
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211238
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211247
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211199
https://www.pharmaceutical-technology.com/news/eisai-bial-zebinix-data/
https://www.pharmacompass.com/pdf/news/aptiom-eslicarbazepine-acetate-bial-portela-ca-sa-v-hetero-labs-1520833326.pdf
https://www.pharmacompass.com/pdf/news/aptiom-eslicarbazepine-acetatebial-portela-ca-sa-v-dr-reddys-lab-1520249835.pdf
https://www.pharmacompass.com/pdf/news/aptiom-eslicarbazepine-acetate-bial-portela-v-jubilant-life-sciences-1520833468.pdf
https://www.pharmacompass.com/pdf/news/aptiom-eslicarbazepine-acetatebial-portela-ca-sa-v-jubilant-1520248928.pdf
https://www.pharmacompass.com/pdf/news/Aptiom-Eslicarbazepine-AcetateBial-Portela-CA-SA-v-Alkem-Laboratories-1520249257.pdf
http://www.pharmatimes.com/news/zebinix_non-inferior_to_current_standard_of_care_in_epilepsy_1219983
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-aptiom-eslicarbazepine-acetate-tablets-1516338003.pdf
http://www.pharmatimes.com/news/real_world_data_back_use_of_eisai,_bials_zebinix_in_epilepsy_1214415
http://www.pharmatimes.com/news/eu_regulators_widen_approval_for_zebinix_1194295
http://www.prnewswire.com/news-releases/neurocrine-and-bial-announce-exclusive-north-american-licensing-agreement-for-opicapone-300405152.html
http://www.prnewswire.com/news-releases/nuevos-datos-de-postcomercializacion-de-zebinix-acetato-de-eslicarbazepina-recopilados-durante-seis-anos-muestran-que-su-perfil-de-seguridad-permanece-sin-cambios-de-acuerdo-a-los-resultados-de-un-estudio-de-practica-clinica-h-581324971.html
http://www.prnewswire.com/news-releases/nuevos-datos-de-postcomercializacion-de-zebinix-acetato-de-eslicarbazepina-recopilados-durante-seis-anos-muestran-que-su-perfil-de-seguridad-permanece-sin-cambios-de-acuerdo-a-los-resultados-de-un-estudio-de-practica-clinica-h-581324971.html
http://www.prnewswire.com/news-releases/bial-und-eisai-geben-neue-daten-bekannt-nach-welchen-einmal-taglich-zebinix-eslicarbazepinacetat-als-monotherapie-gemaW-auf-der-jahresversammlung-der-american-academy-of-neurology-aan-vorgestellter-erster-daten-wirksam-ist--576285711.html
http://www.prnewswire.com/news-releases/presentados-nuevos-datos-de-practica-clinica-sobre-el-uso-de-zebinix-acetato-de-eslicarbazepina-para-tratar-las-crisis-de-inicio-parcial-en-la-reunion-anual-de-la-sociedad-americana-de-epilepsia-aes-561277221.html
http://www.prnewswire.com/news-releases/zebinix-acetate-deslicarbazepine-dans-la-prise-en-charge-des-crises-partielles-depilepsie-nouvelles-analyses-de-donnees-de-vie-reelle-presentees-lors-du-congres-annuel-de-lamerican-epilepsy-society-aes-560733251.html
http://www.prnewswire.com/news-releases/los-resultados-finales-del-estudio-epos-presentados-en-el-congreso-internacional-de-epilepsia-iec-muestran-que-el-tratamiento-adyuvante-con-zebinix-acetato-de-eslicarbazepina-mejora-la-calidad-de-vida-525801711.html
http://processandproduction.pharmaceutical-business-review.com/news/fda-approves-new-indication-for-sunovions-aptiom-as-monotherapy-for-partial-onset-seizures-310815-4659017?utm_term=Pharma&utm_source=PBR&utm_medium=twitter
http://www.businesswire.com/news/home/20150127005166/en/PsychoGenics-Achieves-Milestone-Drug-Discovery-Collaboration-Sunovion#.VMiRcdKUdqU
Market Place
Share 
